The news is by your side.


Roche’s emicizumab haemophilia drug succeeds in trial

SHANGHAI: Roche Holding AG's emicizumab drug for treating haemophilia A showed it worked in a phase III study, the Swiss drugmaker said on Thursday. Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910, which represents a threat to more traditional treatments from Novo Nordisk and Shire. Roche's drug is being closely watched because it could change the way the disease is treated. The study showed a statistically significant reduction in the number of…